Jing Xie1, M Kamran Ikram2, Mary Frances Cotch3, Barbara Klein4, Rohit Varma5, Jonathan E Shaw6, Ronald Klein4, Paul Mitchell7, Ecosse L Lamoureux2, Tien Yin Wong2. 1. Centre for Eye Research Australia, University of Melbourne, East Melbourne, Victoria, Australia. 2. Singapore Eye Research Institute, Singapore National Eye Centre, National University of Singapore, Singapore3Duke-NUS Medical School, National University of Singapore, Singapore. 3. Division of Epidemiology and Clinical Applications, National Eye Institute, Intramural Research Program, National Institutes of Health, Bethesda, Maryland. 4. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison. 5. Department of Ophthalmology and Visual Sciences, University of Illinois College of Medicine at Chicago, Chicago. 6. Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. 7. Centre for Vision Research, Westmead Insitute for Medical Research and University of Sydney, Sydney, New South Wales, Australia.
Abstract
Importance: Previous studies on the relationship between diabetic retinopathy (DR) and cardiovascular disease (CVD) focused on the early stages of DR. Understanding whether patients with type 2 diabetes and severe stages of DR (diabetic macular edema [DME] and proliferative diabetic retinopathy [PDR]) have a higher risk of CVD will allow physicians to more effectively counsel patients. Objective: To examine the association of severe stages of DR (DME and PDR) with incident CVD in patients with type 2 diabetes. Data Sources: English-language publications were reviewed for articles evaluating the relationship of DR and CVD in MEDLINE, EMBASE, Current Contents, and the Cochrane Library from inception (January 1, 1950) to December 31, 2014, using the search terms diabetic retinopathy OR macular edema AND stroke OR cerebrovascular disease OR coronary artery disease OR heart failure OR myocardial infarction OR angina pectoris OR acute coronary syndrome OR coronary artery disease OR cardiomyopathy. Study Selection: Among 656 studies screened for eligibility, 7604 individuals were included from 8 prospective population-based studies with data on photographic-based DR grading, follow-up visits, and well-defined incident CVD end point. Data Extraction and Synthesis: Two independent reviewers conducted a systematic search of the 4 databases, and a single pooled database was developed. Incidence rate ratios (IRRs) were estimated for patients with DME, PDR, and vision-threatening DR, compared with persons without these conditions, by using individual participant data followed by a standard inverse-variance meta-analysis (2-step analysis). The review and analyses were performed from January 1, 2009, to January 1, 2017. Main Outcome and Measures: Incident CVD, including coronary heart disease, stroke, or death from cardiovascular causes. Results: Among 7604 patients with type 2 diabetes, the prevalence of DME was 4.6% and PDR, 7.4%. After a mean follow-up of 5.9 years (range, 3.2-10.1 years), 1203 incident CVD events, including 916 coronary heart disease cases, were reported. Persons with DME or PDR were more likely to have incident CVD (IRR, 1.39; 95% CI, 1.16-1.67) and fatal CVD (IRR, 2.33; 95% CI, 1.49-3.67) compared with those without DME or PDR. Conclusions and Relevance: Patients with type 2 diabetes and DME or PDR have an increased risk of incident CVD, which suggests that these persons should be followed up more closely to prevent CVD.
Importance: Previous studies on the relationship between diabetic retinopathy (DR) and cardiovascular disease (CVD) focused on the early stages of DR. Understanding whether patients with type 2 diabetes and severe stages of DR (diabetic macular edema [DME] and proliferative diabetic retinopathy [PDR]) have a higher risk of CVD will allow physicians to more effectively counsel patients. Objective: To examine the association of severe stages of DR (DME and PDR) with incident CVD in patients with type 2 diabetes. Data Sources: English-language publications were reviewed for articles evaluating the relationship of DR and CVD in MEDLINE, EMBASE, Current Contents, and the Cochrane Library from inception (January 1, 1950) to December 31, 2014, using the search terms diabetic retinopathy OR macular edema AND stroke OR cerebrovascular disease OR coronary artery disease OR heart failure OR myocardial infarction OR angina pectoris OR acute coronary syndrome OR coronary artery disease OR cardiomyopathy. Study Selection: Among 656 studies screened for eligibility, 7604 individuals were included from 8 prospective population-based studies with data on photographic-based DR grading, follow-up visits, and well-defined incident CVD end point. Data Extraction and Synthesis: Two independent reviewers conducted a systematic search of the 4 databases, and a single pooled database was developed. Incidence rate ratios (IRRs) were estimated for patients with DME, PDR, and vision-threatening DR, compared with persons without these conditions, by using individual participant data followed by a standard inverse-variance meta-analysis (2-step analysis). The review and analyses were performed from January 1, 2009, to January 1, 2017. Main Outcome and Measures: Incident CVD, including coronary heart disease, stroke, or death from cardiovascular causes. Results: Among 7604 patients with type 2 diabetes, the prevalence of DME was 4.6% and PDR, 7.4%. After a mean follow-up of 5.9 years (range, 3.2-10.1 years), 1203 incident CVD events, including 916 coronary heart disease cases, were reported. Persons with DME or PDR were more likely to have incident CVD (IRR, 1.39; 95% CI, 1.16-1.67) and fatal CVD (IRR, 2.33; 95% CI, 1.49-3.67) compared with those without DME or PDR. Conclusions and Relevance: Patients with type 2 diabetes and DME or PDR have an increased risk of incident CVD, which suggests that these persons should be followed up more closely to prevent CVD.
Authors: Ning Cheung; Jie Jin Wang; Ronald Klein; David J Couper; A Richey Sharrett; Tien Y Wong Journal: Diabetes Care Date: 2007-03-26 Impact factor: 19.112
Authors: Hiroto Miura; Ruth E Wachtel; Fausto R Loberiza; Takashi Saito; Mamoru Miura; Alfred C Nicolosi; David D Gutterman Journal: Circ Res Date: 2003-02-07 Impact factor: 17.367
Authors: Daniel Gordin; Valma Harjutsalo; Liane Tinsley; Ward Fickweiler; Jennifer K Sun; Carol Forsblom; Peter S Amenta; David Pober; Stephanie D'Eon; Maya Khatri; Isaac E Stillman; Per-Henrik Groop; Hillary A Keenan; George L King Journal: Diabetes Care Date: 2018-01-31 Impact factor: 19.112
Authors: Jonathan Yap; Kamalesh Anbalakan; Wan Ting Tay; Daniel Ting; Carol Yim Cheung; Charumathi Sabanayagam; Ching-Yu Cheng; Tien-Yin Wong; Khung Keong Yeo Journal: BMJ Open Diabetes Res Care Date: 2021-07
Authors: Laima Brazionis; Anthony Keech; Christopher Ryan; Alex Brown; David O'Neal; John Boffa; Sven-Erik Bursell; Alicia Jenkins Journal: BMJ Open Ophthalmol Date: 2021-07-01